BioNTech (NASDAQ:BNTX) announced today its comprehensive participation in the European Lung Cancer Congress (ELCC) 2026, where the company will present updated data across its diversified lung cancer portfolio.
The presentations underscore BioNTech's strategic pivot toward becoming a multi-product oncology company by 2030, with a current pipeline of 16 ongoing lung cancer trials, including four pivotal Phase 3 studies.
A primary highlight of the congress is the updated data for gotistobart (BNT316/ONC-392), a selective Treg-depleting anti-CTLA-4 antibody.
In stage 1 of the global Phase 3 PRESERVE-003 trial, gotistobart demonstrated a 54% reduction in the risk of death compared to standard-of-care docetaxel in patients with metastatic squamous non-small cell lung cancer (sqNSCLC).
With a median overall survival (OS) not yet reached at 15 months—compared to 10 months for chemotherapy—the candidate has already received FDA Fast Track and Orphan Drug designations, positioning it as a potential chemotherapy-free alternative for heavily pre-treated patients.
BioNTech will also provide updates on pumitamig (BNT327), its PD-L1xVEGF-A bispecific immunomodulator.
New data from multiple China-based trials further reinforce the candidate's efficacy and safety profile in both small cell (SCLC) and non-small cell lung cancer (NSCLC).
Pumitamig is the cornerstone of BioNTech's "novel-novel" combination strategy, currently being evaluated in five different combination regimens with other investigational assets, including antibody-drug conjugates (ADCs) and mRNA therapies.
The congress will also feature the first clinical data for BNT326/YL202, a HER3-targeted ADC developed in collaboration with MediLink Therapeutics.
Early findings from a Phase 2 trial conducted in China showed encouraging antitumor activity and a manageable safety profile in patients with advanced NSCLC who progressed after standard therapies.
This data supports the ongoing expansion of the Phase 1b/2 trial evaluating the combination of BNT326 and pumitamig, a pairing that BioNTech believes could offer a differentiated therapeutic profile by simultaneously targeting metabolic and immune-evasion pathways in tumors.